NCT06168357Not yet recruiting
Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma .
Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma Following Locoregional Treatment.
Source: ClinicalTrials.gov · Last updated 13 Dec 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Role of ADC value and DWI in abbreviated MRI compared to post-contrast CT in follow-up of HCC after TACE.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 55 (estimated)
- First submitted
- 5 Dec 2023
- Start date
- Jan 2024
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Assiut University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06168357
What you commit to
- Study type: Observational
- Planned participants: 55
- From Jan 2024 to the primary completion date, 30 Sept 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Estimated GFR less than 60 Previous history of severe allergic reaction to the iodinated contrast agent Patients with claustrophobia who can't undergo MR examination. Patients having cochlear implants or cardiac pacemaker
Who the study is looking for
- Patients who underwent TACE for unresectable HCC with patent portal vein based on Doppler, no ascites, and satisfactory liver function.
- Age between 20-year old and 85-year old
Age in the registry: 20 years to 85 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.